Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACELYRIN, INC. (SLRN)
NASDAQ:SLRN
Holding SLRN?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.8Last Year’s EPS
4.45Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Aug 14, 2023
|% Change Since: -66.72%
|Next Earnings Date:Jun 15, 2023
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant progress in pipeline prioritization and financial management, offset by challenges in clinical development decisions and safety considerations.Company Guidance
During the Q3 2024 earnings call for Acelyrin, Inc., the company provided several key metrics and guidance updates regarding their pipeline progress and financial position. The focus was on their lead product candidate, lonigutamab, targeting thyroid eye disease (TED), with plans to start a Phase III program in Q1 2025, following alignment with the FDA on dosing strategies that allow treatment up to 52 weeks. The company also highlighted their ongoing Phase IIb/III trial of izokibep for uveitis, with top-line results anticipated in December 2024. Financially, Acelyrin ended the quarter with $562.4 million in cash, projecting a year-end cash position between $435 million and $450 million, providing an operational runway through mid-2027. The company reduced research and development expenses to $31.6 million from $74.6 million a year prior, and general and administrative expenses to $12.3 million from $19.9 million, largely due to decreased clinical activity and stock-based compensation, respectively.Strategic Reprioritization of Pipeline
The company has refocused its pipeline to prioritize the development of lonigutamab for thyroid eye disease (TED), showing positive proof-of-concept data with rapid improvements noted within 3 weeks.
Successful Financial Management
The company ended the third quarter with $562.4 million in cash. R&D expenses decreased from $74.6 million in Q3 2023 to $31.6 million in Q3 2024, mainly due to reduced clinical activity in certain trials.
Positive End of Phase II Meeting with FDA
The company completed a positive end of Phase II meeting with the FDA for the lonigutamab program, aligning on important elements for the Phase III registrational program.
Manufacturing Commitments Resolved
Resolved outstanding manufacturing commitments for izokibep, resulting in a net expense of $7.2 million, with a $35.7 million credit voucher for future manufacturing services.
Uveitis Program Progress
Completed enrollment for Phase IIb/III uveitis trial, with results expected in December. Potential for significant market opportunity given its orphan disease status.
---
SLRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SLRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $5.98 | $5.16 | -13.71% |
| Aug 13, 2024 | $4.76 | $4.06 | -14.71% |
| May 13, 2024 | $4.68 | $4.69 | +0.21% |
| Mar 28, 2024 | $6.75 | $6.66 | -1.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ACELYRIN, INC. (SLRN) report earnings?
ACELYRIN, INC. (SLRN) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is ACELYRIN, INC. (SLRN) earnings time?
ACELYRIN, INC. (SLRN) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SLRN EPS forecast?
SLRN EPS forecast for the fiscal quarter 2024 (Q4) is -0.8.
---